FUJIFILM Liver Biomarkers: Aiding in the Early Detection of Hepatocellular Carcinoma (HCC)
Booth #D3233 (second level)
November 10-14, Boston, MA
PRODUCT THEATER
Hepatocellular Carcinoma (HCC) Surveillance Biomarker Landscape Overview
Date & Time: Monday, November 13, 1:30-2:00pm Location: Product Theater 1 (Plaza Level)
HCC surveillance is associated with reduced HCC mortality. However, ultrasound has insufficient sensitivity for early tumor detection, prompting increasing interest in blood-based biomarkers. This session will review the phases of biomarker validation, present the status and data for (protein and liquid biopsy) biomarkers, and discuss ongoing biomarker studies.
Featured speakers:
Amit Singal, MD, MS
Professor, Medical Director of the Liver Tumor Program, and Chief of Hepatology
UT Southwestern Medical Center
Neehar Parikh, MD, MS
Assistant Professor, Medical Director of the Multidisciplinary Liver Tumor Clinic, and Medical Director of the Living Donor Liver Transplantation Program
University of Michigan
Moderated by:
Laura M. Kulik, MD
Professor of Medicine, Interventional Radiology, and Transplant Surgery
Northwestern Feinberg School of Medicine
FUJIFILM HCC Risk Biomarkers
AFP-L3 and DCP are in vitro diagnostic serum biomarkers for use in patients at risk for hepatocellular carcinoma
AFP-L3: Lectin-reactive alpha-fetoprotein; DCP: Des-gamma-carboxy prothrombin
AFP-L3% ≥10%: Associated with 10.6-fold increased risk of developing HCC1
DCP ≥7.5 ng/mL: Associated with 4.8-fold increased risk of developing HCC1
Both biomarkers are commercially available through major US reference labs and are available for reimbursement by Centers for Medicare & Medicaid Services (CMS).
Overview of Intended Uses (See package inserts): The μTASWako AFP-L3 and DCP test systems are in vitro devices that consist of reagents used with the μTASWako i30 Immunoanalyzer to quantitatively measure, by immunochemical techniques, AFP-L3% and DCP in human serum. Both devices are intended for IVD use as aids in the risk assessment of patients with chronic liver disease for development of HCC in conjunction with other laboratory findings, imaging studies and clinical assessment.1
To learn more, please visit our website at ivd.fujimed.com.
While Attending The Liver Meeting® 2023, Come Check out the Poster Presentations featuring FUJIFILM Biomarkers
Poster Presentation
Publication Number: 1129-A
Poster Title: A Novel HCC Waitlist Dropout Score Biomarker Integrated Dropout Gradient Estimation (BRIDGE)
Date, Time, Location: Friday, November 10th, 12:00 PM- 1:00 PM, Hall A
Authors: Jonathan Li, Mr. Jeff Liang, Dr. Vatche G. Agopian, Dr. Kelley Nunez, Mr. Joshua Norman, Naomy Kim, Mr. Jung Yum, Shreya Gumate, Dr. Ari J. Cohen, Dr. Kambiz Kosari, Dr. Nicholas Nissen, Dr. Francis Yao, Dr. Paul Thevenot, Dr. Ju Dong Yang and Dr. Neil Mehta
Reference:
- µTASWako i30 Analyzer and AFP-L3 & DCP Test Systems Package Inserts.
The Liver Meeting® is a registered trademark of the American Association for the Study of Liver Diseases.
© 2023 FUJIFILM Healthcare Americas Corporation. All rights reserved.
